David Tuveson

Last updated
David Tuveson
Born (1966-01-01) January 1, 1966 (age 57)
NationalityAmerican
Alma mater Massachusetts Institute of Technology
Johns Hopkins School of Medicine
Known forDeveloping mouse and organoid models of pancreatic cancer
AwardsRita Allen Foundation Scholar Award
2022 Luminary Award
Scientific career
FieldsCancer biology
Institutions Cold Spring Harbor Laboratory
University of Pennsylvania
Cambridge Research Institute
Doctoral advisor Douglas Fearon

David Arthur Tuveson (born January 1, 1966) is an American cancer biologist and is currently Roy J. Zuckerberg Professor of Cancer Research as well as The Cancer Center Director at Cold Spring Harbor Laboratory. Dr. Tuveson is also the Chief Scientist for the Lustgarten Foundation for Pancreatic Cancer Research. [1] He is known for developing some of the first mouse models of pancreatic cancer and more recently, for his work developing pancreatic cancer organoids. [2] [3]

Contents

Education and training

David Tuveson received a B.S. in chemistry from the Massachusetts Institute of Technology in 1987. He received an M.D. and Ph.D. from the Johns Hopkins School of Medicine in 1994, where his Ph.D. adviser was Douglas Fearon. He completed a residency at Brigham and Women's Hospital from 1994-1997. From 1997-2000, he pursued a Fellowship in Hematology and Oncology at the Dana–Farber Cancer Institute. During this time, he also performed postdoctoral research in mouse models of lung cancer in the laboratory of Tyler Jacks at the Massachusetts Institute of Technology. [4]

Career

Following completion of his fellowship training, Tuveson started his own laboratory at the University of Pennsylvania, where he was an assistant professor of medicine from 2002 to 2006. [5] In 2006, he moved to the Cambridge Research Institute, where he was a senior group leader and a professor of pancreatic cancer medicine. In 2012, he took a position as a group leader and the deputy director of the Cancer Center at Cold Spring Harbor Laboratory. [5] In 2016, Tuveson assumed the position of Director of the Cold Spring Harbor Laboratory Cancer Center. [6] He served as the President for the American Association for Cancer Research from 2021 to 2022. [7] He is a member of the editorial board for Oncogene , [8] Journal of Experimental Medicine , [9] and Cancer Discovery (journal) . [10] He also serves on the scientific advisory board for Leap Therapeutics [11] and the Board of Scientific Advisors for the National Cancer Institute. [12] In 2020, Tuveson was elected as Fellow of the American Association for Cancer Research, [13] and in 2022, he was elected to the National Academy of Medicine. [14] He also co-founded the biotechnology company Mestag Therapeutics in 2021. [15] [16]

Research

During his postdoctoral training in the Jacks Laboratory, Tuveson learned how to engineer mouse models to study human cancer. [4] During this time, he also studied gastrointestinal stromal tumors (GISTs), and worked with Dr. George Demetri to develop imatinib as a treatment for GIST. [17] When he started his own laboratory at the University of Pennsylvania, Tuveson developed some of the first genetically engineered mouse models to aid in the study of pancreatic cancer. [4] [18] [19] Using these mice, Tuveson has made several important discoveries in the biology of pancreatic cancer, including the work that contributed to the idea that the stromal cells of pancreatic tumors act as a barrier for therapies. [20] He later partnered with Hans Clevers to develop pancreatic cancer organoids – tumor cells taken from a human patient and cultured in the laboratory as three-dimensional spheres. [21] In 2017, he partnered with the National Cancer Institute to develop organoids for use more broadly by the cancer research community. [22]

Honors and awards

David Tuveson was given an AACR-PanCAN Career Development Award in Pancreatic Cancer research in 2003. He was also the recipient of an M.L. Smith Award in 2003, a Rita Allen Foundation Scholar Award in 2004, and a Distinguished Scholar Award from the Lustgarten Foundation. He was awarded Hamdan Award for Medical Research Excellence - Pancreatic Diseases by Hamdan Medical Award in 2016. He received a 2022 Luminary Award [23] and was on Clarivate’s list of the top most cited researchers in 2022. [24]

Major publications

Tuveson has an h-index of 102 according to Google Scholar. [25] Some of his most important publications are:


Related Research Articles

<span class="mw-page-title-main">Pancreatic cancer</span> Type of endocrine gland cancer

Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to multiply out of control and form a mass. These cancerous cells have the ability to invade other parts of the body. A number of types of pancreatic cancer are known.

<span class="mw-page-title-main">Keratin 7</span>

Keratin, type II cytoskeletal 7 also known as cytokeratin-7 (CK-7) or keratin-7 (K7) or sarcolectin (SCL) is a protein that in humans is encoded by the KRT7 gene. Keratin 7 is a type II keratin. It is specifically expressed in the simple epithelia lining the cavities of the internal organs and in the gland ducts and blood vessels.

<span class="mw-page-title-main">Bert Vogelstein</span> American oncologist (born 1949)

Bert Vogelstein is director of the Ludwig Center, Clayton Professor of Oncology and Pathology and a Howard Hughes Medical Institute investigator at The Johns Hopkins Medical School and Sidney Kimmel Comprehensive Cancer Center. A pioneer in the field of cancer genomics, his studies on colorectal cancers revealed that they result from the sequential accumulation of mutations in oncogenes and tumor suppressor genes. These studies now form the paradigm for modern cancer research and provided the basis for the notion of the somatic evolution of cancer.

<span class="mw-page-title-main">Organoid</span> Miniaturized and simplified version of an organ

An organoid is a miniaturized and simplified version of an organ produced in vitro in three dimensions that mimics the key functional, structural and biological complexity of that organ. They are derived from one or a few cells from a tissue, embryonic stem cells or induced pluripotent stem cells, which can self-organize in three-dimensional culture owing to their self-renewal and differentiation capacities. The technique for growing organoids has rapidly improved since the early 2010s, and The Scientist names it as one of the biggest scientific advancements of 2013. Scientists and engineers use organoids to study development and diseases in the laboratory and industry for drug discovery and development, personalized diagnostics and medicine, gene and cell therapies, tissue engineering and regenerative medicine.

<span class="mw-page-title-main">Palladin</span> Protein-coding gene in the species Homo sapiens

Palladin is a protein that in humans is encoded by the PALLD gene. Palladin is a component of actin-containing microfilaments that control cell shape, adhesion, and contraction.

<span class="mw-page-title-main">Victor Velculescu</span>

Victor E. Velculescu is a Professor of Oncology and Co-Director of Cancer Biology at Johns Hopkins University School of Medicine. He is internationally known for his discoveries in genomics and cancer research.

<span class="mw-page-title-main">Peptide transporter 1</span> Mammalian protein found in Homo sapiens

Peptide transporter 1 also known as solute carrier family 15 member 1 (SLC15A1) is a protein that in humans is encoded by SLC15A1 gene. PepT 1 is a solute carrier for oligopeptides. It functions in renal oligopeptide reabsorption and in the intestines in a proton dependent way, hence acting like a cotransporter.

<span class="mw-page-title-main">PAX4</span> Protein-coding gene in humans

Paired box gene 4, also known as PAX4, is a protein which in humans is encoded by the PAX4 gene.

<span class="mw-page-title-main">MTAP</span> Protein-coding gene in the species Homo sapiens

S-methyl-5'-thioadenosine phosphorylase (MTAP) is an enzyme in humans responsible for polyamine metabolism. It is encoded by the methylthioadenosine phosphorylase (MTAP) gene on chromosome 9. Multiple alternatively spliced transcript variants have been described for this gene, but their full-length natures remain unknown.

<span class="mw-page-title-main">AGR2</span> Protein-coding gene in the species Homo sapiens

Anterior gradient protein 2 homolog (AGR-2), also known as secreted cement gland protein XAG-2 homolog, is a protein that in humans is encoded by the AGR2 gene. Anterior gradient homolog 2 was originally discovered in Xenopus laevis. In Xenopus AGR2 plays a role in cement gland differentiation, but in human cancer cell lines high levels of AGR2 correlate with downregulation of the p53 response, cell migration, and cell transformation. However, there have been other observations that AGR2 can repress growth and proliferation.

Neurogenins, often abbreviated as Ngn, are a family of bHLH transcription factors involved in specifying neuronal differentiation. The family consisting of Neurogenin-1, Neurogenin-2, and Neurogenin-3, plays a fundamental role in specifying neural precursor cells and regulating the differentiation of neurons during embryonic development. It is one of many gene families related to the atonal gene in Drosophila. Other positive regulators of neuronal differentiation also expressed during early neural development include NeuroD and ASCL1.

<span class="mw-page-title-main">PALB2</span> Protein-coding gene in the species Homo sapiens

Partner and localizer of BRCA2, also known as PALB2 or FANCN, is a protein which in humans is encoded by the PALB2 gene.

<span class="mw-page-title-main">FAM3C</span> Protein-coding gene in the species Homo sapiens

Protein FAM3C is a protein that in humans is encoded by the FAM3C gene.

A humanized mouse is a mouse carrying functioning human genes, cells, tissues, and/or organs. Humanized mice are commonly used as small animal models in biological and medical research for human therapeutics.

Tyler Jacks is a David H. Koch Professor of Biology at the Massachusetts Institute of Technology (MIT), a long-time HHMI investigator, and Founding Director of the David H. Koch Institute for Integrative Cancer Research, which brings together biologists and engineers to improve detection, diagnosis, and treatment of cancer. Dr. Jacks is a member of the board of directors of Thermo Fisher Scientific and Amgen, two of the major biotechnology corporations in the world. He is the President of Break Through Cancer, a foundation dedicated to supporting multi-institutional teams of researchers focused on finding solutions to some of the most difficult to treat cancers. He is also a member of the Board of Overseers, the larger of two governing boards of Harvard University.

<span class="mw-page-title-main">12-Hydroxyeicosatetraenoic acid</span> Chemical compound

12-Hydroxyeicosatetraenoic acid (12-HETE) is a derivative of the 20 carbon polyunsaturated fatty acid, arachidonic acid, containing a hydroxyl residue at carbon 12 and a 5Z,8Z,10E,14Z Cis–trans isomerism configuration (Z=cis, E=trans) in its four double bonds. It was first found as a product of arachidonic acid metabolism made by human and bovine platelets through their 12S-lipoxygenase (i.e. ALOX12) enzyme(s). However, the term 12-HETE is ambiguous in that it has been used to indicate not only the initially detected "S" stereoisomer, 12S-hydroxy-5Z,8Z,10E,14Z-eicosatetraenoic acid (12(S)-HETE or 12S-HETE), made by platelets, but also the later detected "R" stereoisomer, 12(R)-hydroxy-5Z,8Z,10E,14Z-eicosatetraenoic acid (also termed 12(R)-HETE or 12R-HETE) made by other tissues through their 12R-lipoxygenase enzyme, ALOX12B. The two isomers, either directly or after being further metabolized, have been suggested to be involved in a variety of human physiological and pathological reactions. Unlike hormones which are secreted by cells, travel in the circulation to alter the behavior of distant cells, and thereby act as Endocrine signalling agents, these arachidonic acid metabolites act locally as Autocrine signalling and/or Paracrine signaling agents to regulate the behavior of their cells of origin or of nearby cells, respectively. In these roles, they may amplify or dampen, expand or contract cellular and tissue responses to disturbances.

<span class="mw-page-title-main">GUCY2F</span> Protein-coding gene in humans

Retinal guanylyl cyclase 2 also known as guanylate cyclase F (GUCY2F) is a protein that in humans is encoded by the GUCY2F gene.

The American Association for Cancer Research gives several annual awards for significant contributions to the field of cancer research.

<span class="mw-page-title-main">Uwe Marx</span>

Uwe Marx is a German physician and biotechnologist, and one of the world’s leading researchers in the fields of organ-on-a-chip technology and antibody production.

<span class="mw-page-title-main">Dannielle Engle</span> American biologist

Dannielle Engle is an American biologist and assistant professor of the regulatory biology laboratory at the Salk Institute for Biological Studies. Engle’s research aims at improving detection and treatment of pancreatic cancer.

References

  1. ↑ "Tuveson Lab - Lustgarten Foundation".
  2. ↑ "Mice Model a Silent Killer". The Scientist.
  3. ↑ "Ability to culture 'organoids' set to transform pancreatic cancer research". Medical News Today . 2015-01-04.
  4. 1 2 3 "Propelling Progress in Pancreatic Cancer Research". American Association of Cancer Research.
  5. 1 2 "David Tuveson Profile". Cold Spring Harbor Laboratory.
  6. ↑ "Dr. David Tuveson named Director, NCI-Designated Cancer Center at Cold Spring Harbor Laboratory". Cold Spring Harbor Laboratory.
  7. ↑ "David A. Tuveson, MD PhD, FAACR".
  8. ↑ "Editorial Board | Oncogene".
  9. ↑ "Editors and Staff - Journal of Experimental Medicine".
  10. ↑ "Editors - Cancer Discovery".
  11. ↑ "About - Leap Therapeutics, Inc".
  12. ↑ "National Cancer Institute Board of Scientific Advisors" (PDF).
  13. ↑ "David A. Tuveson - AACR - Fellow".
  14. ↑ "David Tuveson elected to National Academy of Medicine".
  15. ↑ "About - Mestag Therapeutics".
  16. ↑ "Mestag Therapeutics launches with seed financing of $11 million to develop therapeutics targeting activated fibroblast populations across inflammatory disease and cancer".
  17. ↑ Demetri, George M.; von Mehren, Margaret; Blanke, Charles D.; Van den Abbeele, Annick D.; Eisenberg, Burton; Roberts, Peter J.; Heinrich, Michael C.; Tuveson, David A.; Singer, Samuel; Janicek, Milos; Fletcher, Jonathan A.; Silverman, Stuart G.; Silberman, Sandra L.; Capdeville, Renaud; Kiese, Beate; Peng, Bin; Dimitrijevic, Sasa; Druker, Brian J.; Corless, Christopher; Fletcher, Christopher D.M.; Joensuu, Heikki (2002). "Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors". New England Journal of Medicine. 347 (7): 472–480. doi: 10.1056/NEJMoa020461 . PMID   12181401. S2CID   46098916.
  18. ↑ Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, Kawaguchi Y, Johann D, Liotta LA, Crawford HC, Putt ME, Jacks T, Wright CV, Hruban RH, Lowy AM, Tuveson DA (2003). "Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse". Cancer Cell. 4 (6): 437–450. doi: 10.1016/S1535-6108(03)00309-X . PMID   14706336.
  19. ↑ Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, Rustgi AK, Chang S, Tuveson DA (2005). "Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice". Cancer Cell. 7 (5): 469–483. doi: 10.1016/j.ccr.2005.04.023 . PMID   15894267.
  20. ↑ Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, Ireland-Zecchini H, Reichelt S, Howat WJ, Chang A, Dhara M, Wang L, Rückert F, Grützmann R, Pilarsky C, Izeradjene K, Hingorani SR, Huang P, Davies SE, Plunkett W, Egorin M, Hruban RH, Whitebread N, McGovern K, Adams J, Iacobuzio-Donahue C, Griffiths J, Tuveson DA (2009). "Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer". Science. 324 (5933): 1457–1461. Bibcode:2009Sci...324.1457O. doi:10.1126/science.1171362. PMC   2998180 . PMID   19460966.
  21. ↑ Boj SF, Hwang CI, Baker LA, Chio II, Engle DD, Corbo V, Jager M, Ponz-Sarvise M, Tiriac H, Spector MS, Gracanin A, Oni T, Yu KH, van Boxtel R, Huch M, Rivera KD, Wilson JP, Feigin ME, Öhlund D, Handly-Santana A, Ardito-Abraham CM, Ludwig M, Elyada E, Alagesan B, Biffi G, Yordanov GN, Delcuze B, Creighton B, Wright K, Park Y, Morsink FH, Molenaar IQ, Borel Rinkes IH, Cuppen E, Hao Y, Jin Y, Nijman IJ, Iacobuzio-Donahue C, Leach SD, Pappin DJ, Hammell M, Klimstra DS, Basturk O, Hruban RH, Offerhaus GJ, Vries RG, Clevers H, Tuveson DA (2015). "Organoid models of human and mouse ductal pancreatic cancer". Cell. 160 (1–2): 324–338. doi:10.1016/j.cell.2014.12.021. PMC   4334572 . PMID   25557080.
  22. ↑ "CSHL to lead international team developing next-generation organoid cancer research". Cold Spring Harbor Laboratory.
  23. ↑ "OncLive and the Ruesch Center for the Cure of Gastrointestinal Cancers Name Winners of the 2022 Luminary Awards in Gastrointestinal Cancers".
  24. ↑ "Highly Cited Researchers - Clarivate".
  25. ↑ "David Tuveson". Google Scholar . Retrieved 6 January 2023.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.